Bioinfra Life Science, Inc.

As of March 31, 2020, Bioinfra Life Science, Inc. has 14.09M shares outstanding.

As of March 31, 2020, Bioinfra Life Science, Inc. maintains a current ratio of 1.67, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -364.91, indicating conservative leverage, while an interest coverage ratio of -10.75 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended March 31, 2020. Return on assets (ROA) is negative at -45.46, reflecting losses generated across the asset base. The company generates approximately 43.92M in revenue per employee across its workforce of 40.50, a quick read on workforce productivity versus industry peers.

As of the close on October 23, 2026, Bioinfra Life Science, Inc.'s stock has declined approximately 60.42% over the past 52 weeks. The 50-day moving average sits at 104.18, while the 200-day moving average is 138.60.

Over the twelve months ended March 31, 2020, Bioinfra Life Science, Inc. generated 1.78B in revenue and converted that into -3.59B in net income, yielding earnings per share of -266.58. EBITDA reached -3.18B, while operating income came in at -3.55B.

As of March 31, 2020, Bioinfra Life Science, Inc. holds 7.49B in cash and equivalents against 4.40B in total debt, resulting in a net debt position of 4.01B. Total book value stands at -1.39B, with working capital of 3.58B providing operational flexibility.

Bioinfra Life Science, Inc. produced -2.87B in operating cash flow over the twelve months ended March 31, 2020. After subtracting -81.61M in capital expenditures, free cash flow totaled -2.95B - equivalent to -219.17 per share.

Over the twelve months ended March 31, 2020, Bioinfra Life Science, Inc. posted a gross margin of 47.46, reflecting its pricing power and cost economics. The operating margin of -199.78 and net profit margin of -202.04 provide insight into operational efficiency.